Monocyte locomotion inhibitory factor
AssigneeCenter for Blood Research, Inc.
InventorRoberto Rodolfo Kretschmer Schmid
Life of this patent
Estimating the term…
Abstract
The invention relates to an anti-inflammatroy oligopeptide which can be obtained from the microorganism Entamoeba histolytica or synthesized by known methods. The oligopeptides are useful in treating inflammatory diseases when formulated in pharmaceutical compositions for administration to patients.
Claims56
A composition comprising an isolated oligopeptide derived from Entamoeba histolytica which is capable of inhibiting the locomotion of macrophages, or a biologically active analogue thereof.
A composition comprising an oligopeptide having the amino acid sequence set forth in SEQ ID NO:1, or a biologically active analogue thereof.
A composition comprising an oligopeptide having the amino acid sequence set forth in SEQ ID NO:2, or a biologically active analogue thereof.
A homodimer comprising a pair of oligopeptides, each oligopeptide having the amino acid sequence set forth in SEQ ID NO:1, or a biologically active analogue thereof.
A heterodimer comprising the oligopeptide of SEQ ID NO:1 which is covalently linked to another and different peptide.
A heterodimer comprising the oligopeptide of SEQ ID NO:1 which is bound to a chemical entity.
A homodimer comprising a pair of the oligopeptides, each oligopeptide having the amino acid sequence set forth in SEQ ID NO:2, or a biologically active analogue thereof.
A heterodimer comprising the oligopeptide of SEQ ID NO:2 which is linked to another and different peptide.
A heterodimer comprising the oligopeptide of SEQ ID NO:2 which is bound to a chemical entity.
A method for treating a subject having an inflammatory condition comprising administering to the subject an oligopeptide having the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or a biologically active analogue thereof, in an amount effective to reduce the inflammation.
A method for inhibiting scar formation resulting from an inflammatory condition comprising administering to the subject an oligopeptide having the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or a biologically active analogue thereof, in an amount effective to reduce scarring.
A method for inhibiting leukocytes in proximity to the site of an inflammatory condition in a subject comprising administering to the subject an oligopeptide having the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or a biologically active analogue thereof, in an amount effective to inhibit said leukocytes.
A method for inhibiting the metabolic activity of macrophages or neutrophils in a subject, said method comprising administering to the subject an oligopeptide having the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or a biologically active analogue thereof, in an amount effective to inhibit the metabolic activity of said macrophages or neutrophils.
A method for inhibiting the activation of the transcription factors NF-κB and AP-1 in a subject due to an inflammatory condition comprising administering to the subject an oligopeptide having the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or a biologically active analogue thereof, in an amount effective to inhibit activation of said transcription factors.
A pharmaceutical composition for treating an inflammatory condition in a subject comprising an oligopeptide having the amino acid sequence set forth in SEQ ID NO:1, SEQ ID NO:2, or a biologically active analogue thereof, and a pharmaceutically acceptable carrier.
An isolated nucleic acid which encodes an oligopeptide having the amino acid sequence set forth in SEQ ID NO:1, SEQ ID NO:2, or a biologically active analogue thereof.
An anti-amoebic vaccine effective against amoebic invasion comprising an oligopeptide having the amino acid sequence set forth in SEQ ID NO:1, SEQ ID NO:2, or a biologically active analogue thereof, and a pharmaceutically acceptable carrier.
A method for identifying an agonist for the MLIF peptide comprising:
- providing a sample containing a candidate agonist molecule,
- providing a cell containing a receptor for the MLIF peptide,
- contacting the candidate molecule and receptor-containing cell, and
- measuring the effect of the candidate molecule on a response mediated through the MLIF receptor.
A high-throughput screening assay for identifying an MLIF agonist comprising:
- providing a sample containing at least one candidate agonist molecule,
- providing a cell containing a receptor for the MLIF peptide,
- contacting the sample with the receptor-containing cell, and
- measuring the effect of the candidate molecule on a response mediated through MLIF receptor.
A method for identifying an antagonist for the MLIF peptide comprising:
- providing a sample containing a candidate antagonist molecule,
- providing a cell containing a receptor for the MLIF peptide,
- providing the MLIF peptide or a biologically active analogue thereof,
- contacting the candidate molecule, MLIF peptide and receptor-containing cell, and
- measuring the effect of the candidate molecule on a response mediated through the MLIF receptor.
A high-throughput screening assay for identifying an MLIF antagonist comprising:
- providing a sample containing at least one candidate antagonist molecule,
- providing a cell containing a receptor for the MLIF peptide,
- providing the MLIF peptide or a biologically active analogue thereof,
- contacting the sample, MLIF peptide and receptor-containing cell, and
- measuring the effect of the candidate molecule on a response mediated through the MLIF receptor.
Dependencies are inferred from the claim text.